Tesamorelin vs CJC-1295 · research class comparison
Tesamorelin vs CJC-1295: two GHRH analogs, but not the same size or structure.
Tesamorelin and CJC-1295 get compared constantly because both are growth-hormone-releasing-hormone (GHRH) analogs — research compounds that act on the same part of the GH axis. But that shared family hides a real structural difference. Tesamorelin is a full-length analog of GHRH(1-44) — all 44 residues — carrying a small acyl (trans-3-hexenoyl) group on its N-terminus to slow enzymatic breakdown. CJC-1295 is a shorter analog based on GHRH(1-29), the truncated 29-residue active fragment, with its own stabilising substitutions; in its no-DAC form (Mod GRF 1-29) it is short-acting, while the DAC version adds an albumin-binding group for a longer window. Forty-four residues versus twenty-nine is not a footnote — it changes how each is synthesised, what can go wrong, and how a credible release sheet has to verify it. This page lays out the split in plain research terms. It makes no fat-loss, growth-hormone, body-composition, or human-use claim about either compound. Tesamorelin is not a Titan SKU; CJC-1295 is stocked as part of an in-house-tested blend, covered below.
Tesamorelin is a full-length 44-residue GHRH
Tesamorelin is an analog of the complete GHRH(1-44) sequence — all forty-four residues — with a trans-3-hexenoyl group attached to the N-terminus. That N-terminal acylation is the point of the modification: it protects the vulnerable front of the peptide from the DPP-4 enzyme that clips native GHRH apart quickly. Because it keeps the full-length backbone, Tesamorelin is the larger of the two molecules, and its identity is a question of the correct 44-mer sequence plus the correct N-terminal group.
Where to buy Tesamorelin →CJC-1295 is a shorter 29-residue analog
CJC-1295 is built on GHRH(1-29) — the truncated 29-residue fragment that retains GHRH activity — with substitutions that make it more stable than the native fragment. It comes in two forms researchers should not confuse: the no-DAC version (Mod GRF 1-29) is short-acting, while the DAC version carries a drug-affinity-complex group that binds albumin and greatly extends its half-life. Titan's in-stock blend pairs the no-DAC form with Ipamorelin, so the short, pulse-like kinetics are the relevant profile there — not the long DAC window buyers often assume.
CJC-1295 half-life explained →Why the length difference actually matters
A 44-residue peptide has fifteen more amino acids to assemble correctly than a 29-residue one, and every extra residue is another place a synthesis run can drop or misplace a unit. Longer chains carry more risk of truncated or deletion sequences that a bare purity number never reveals. So the same 'GHRH analog' label sits on two molecules with different manufacturing risk profiles: Tesamorelin's longer backbone plus its N-terminal group, versus CJC-1295's shorter chain plus its DAC-or-no-DAC question. Neither is 'better' as a research target — they are just different, and the comparison is mechanistic only.
Ipamorelin vs Sermorelin →The release sheets verify different things
For Tesamorelin, a credible certificate confirms the full 44-residue sequence by mass spectrometry, verifies the N-terminal acyl modification is present (it changes the mass), and resolves purity against an HPLC chromatogram — watching for truncated sequences the long chain can hide. For CJC-1295, the sheet confirms the 29-residue analog, states clearly whether it is the DAC or no-DAC form (they are different masses and different molecules), and — in a blend like Titan's — proves both the CJC-1295 and the Ipamorelin components separately. A generic badge that names neither the length nor the DAC status is not verification.
CJC-1295 COA red flags →Both are GHRH analogs, not GHRPs
One clarification that keeps buyers straight: Tesamorelin and CJC-1295 are both GHRH analogs — they mimic growth-hormone-releasing hormone. That is a different mechanism family from the growth-hormone-releasing peptides (GHRPs) like Ipamorelin, which act on a separate receptor. This is exactly why the popular in-stock approach pairs a GHRH analog (CJC-1295) with a GHRP (Ipamorelin): two different receptors rather than two of the same. Tesamorelin, by contrast, is a GHRH analog used on its own in the research literature.
CJC-1295 vs Ipamorelin →What Titan actually stocks
Titan does not stock standalone Tesamorelin. What it does stock is the CJC-1295 + Ipamorelin blend — an in-house-tested combination of the no-DAC 29-residue GHRH analog with the GHRP Ipamorelin. For a researcher who arrived here weighing GHRH analogs, that blend is the in-catalog option Titan actually verifies and can release with a lot-matched sheet. Rather than list a 44-mer it does not test in-house, Titan points to what it does test and to the verification standard that applies to any research peptide, Tesamorelin included.
CJC-1295 + Ipamorelin (in stock) →The detail, in plain terms
The split, in plain terms.
Tesamorelin and CJC-1295 are both GHRH analogs, but Tesamorelin keeps the full 44-residue backbone with an N-terminal modification while CJC-1295 is a shorter 29-residue analog with a DAC-or-no-DAC choice. Chain length and modification — not the shared 'GHRH' label — decide what a release sheet has to prove.
- Tesamorelin — what it is
- Full-length GHRH(1-44) analog with an N-terminal trans-3-hexenoyl group; 44 residues.
- CJC-1295 — what it is
- GHRH(1-29)-based analog, 29 residues; comes in short-acting no-DAC and long-acting DAC forms.
- Same mechanism family?
- Yes — both are GHRH analogs (distinct from GHRPs like Ipamorelin).
- Tesamorelin identity check
- Full 44-mer sequence by MS + confirm N-terminal acyl group; HPLC purity, watch truncation.
- CJC-1295 identity check
- 29-mer analog by MS; state DAC vs no-DAC clearly; blend must prove both components.
- Titan stocks
- Not Tesamorelin — the in-stock CJC-1295 + Ipamorelin blend ($119.99).
Questions researchers ask
Before you order.
- What is the main difference between Tesamorelin and CJC-1295?
- Both are GHRH analogs, but they differ in size and structure. Tesamorelin is a full-length analog of GHRH(1-44) — all 44 residues — with a trans-3-hexenoyl group on the N-terminus to resist enzymatic breakdown. CJC-1295 is based on the shorter GHRH(1-29) fragment (29 residues) with its own stabilising substitutions, and comes in a short-acting no-DAC form and a long-acting DAC form. This is a research and structural comparison only, with no human-use or effect claim for either.
- Is CJC-1295 the DAC or no-DAC form in Titan's blend?
- Titan's in-stock CJC-1295 + Ipamorelin blend uses the no-DAC form (Mod GRF 1-29), which is short-acting — its kinetics are pulse-like rather than the extended window the DAC (drug-affinity-complex) version produces. This matters because buyers often assume any 'CJC-1295' is the long-acting DAC version. A credible release sheet should state DAC vs no-DAC explicitly, since they are different masses and different molecules. See the CJC-1295 half-life page for the details.
- Why does the 44 vs 29 residue difference matter for a COA?
- A 44-residue peptide has fifteen more amino acids to assemble than a 29-residue one, and each extra residue is another place a synthesis run can drop or misplace a unit — so a longer chain carries more risk of truncated or deletion sequences that a bare purity number won't show. A Tesamorelin certificate therefore confirms the full 44-mer sequence by mass spectrometry and verifies the N-terminal modification, while a CJC-1295 certificate confirms the 29-mer analog and states its DAC status. The verification job is genuinely different for each.
- Does Titan sell Tesamorelin?
- No — standalone Tesamorelin is not a Titan catalog product. Titan stocks the CJC-1295 + Ipamorelin blend, an in-house-tested combination of the no-DAC 29-residue GHRH analog with the GHRP Ipamorelin. Rather than list a 44-residue peptide it does not verify in-house, Titan points researchers to the blend it does test and to the COA standard that applies to any research compound, Tesamorelin included.
- Are Tesamorelin or CJC-1295 for human use?
- No. Anything discussed here is strictly for in-vitro laboratory research. Neither Tesamorelin nor CJC-1295 is for human or animal consumption, diagnostic, therapeutic, or preventative use, and no growth-hormone, fat-loss, or body-composition outcome is claimed for either. Nothing on this page is a dosing schedule or a human-use protocol — it is a structure and verification comparison only.